- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07777835
Magnesium Sulphate With Atropine and Pralidoxime vs Standard Therapy Alone in Acute Organophosphate Poisoning
August 17, 2026 updated by: Muhammad Aamir Latif
Comparison of the Efficacy of Adjunctive Magnesium Sulphate With Standard Atropine and Pralidoxime Therapy vs Standard Therapy Alone in Acute Organophosphate Poisoning
Pakistan, being a developing country, is one of the regions with the most cases of organophosphate (OP) poisoning/toxicity.
MgSO4 is one of the most promising adjunctive treatments that needs to be tested.
This study is being carried out with the objective of comparing the 15-day all-cause mortality rate and the total cumulative atropine requirement during hospitalization between patients receiving adjunctive magnesium sulphate with standard therapy and those receiving standard therapy alone.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The current standard therapy in OP is lacking in managing the Intermediate Syndrome (IMS) and the delayed complications.
This deficiency underscores the need for carrying out research to test the efficacy of adjunct compounds in the better management of the toxicity of this deadly substance.
MgSO4 is one of the most promising adjunctive treatments that needs to be tested.
In a setting where economic instability and a compromised health system put an uneven burden on the shoulders of the patient, introducing a regimen that could possibly reduce the hospital stay and prevent the use of ventilators can be very healthy for the pockets of the government bodies as well as the patient's attendants.
Assessing atropine consumption, need for mechanical ventilation, incidence of respiratory failure due to IMS, length of hospital admission, and mortality in the treatment would enable clinicians to recognize whether the adjunctive treatment is efficacious in achieving reasonable outcomes or not.
Study Type
Interventional
Enrollment (Estimated)
38
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sana Usman
- Phone Number: +923007154668
- Email: sunusman0@gmail.com
Study Contact Backup
- Name: Arif Mahmood, FCPS
- Phone Number: +923008730810
- Email: dr_arif_mahmood@yahoo.com
Study Locations
-
-
Punjab Province
-
Multan, Punjab Province, Pakistan, 60000
- Recruiting
- Nishtar Hospital/Medical University
-
Contact:
- Sana Usman
- Phone Number: +923007154668
- Email: sunusman0@gmail.com
-
Contact:
- Arif Mahmood, FCPS
- Phone Number: +923008730810
- Email: dr_arif_mahmood@yahoo.com
-
Principal Investigator:
- Sana Usman
-
Principal Investigator:
- Arif Mahmood
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Both genders
- Adult patients aged between 18 and 50 years
- Confirmed clinical diagnosis of organophosphate poisoning containing insecticide, through the oral route
- Adult patients, or their legally authorized representative, who will provide informed consent to participate in the study
Exclusion Criteria:
- Patients with known allergy to MgSO4
- Patients with documented pre-existing renal impairment (Serum creatinine more than 1.5mg/dl)
- Patients with documented pre-existing cardiac impairments (e.g., heart block)
- Pregnant or lactating women
- Confirmed intake of any other drug or poison
- Patients who will be declared dead on arrival or those who expired within 2 hours of presentation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Atropine plus pralidoxime with MgSO4-Group
Patients will be treated with standard atropine and pralidoxime therapy along with adjunctive MgSO4 (loading dose of 4g in 100ml N/S intravenous infusion over 30 minutes, followed by 1g/hr in 100ml N/S continuous IV infusion for 24 hours).
|
Patients will be treated with standard atropine and pralidoxime therapy along with adjunctive MgSO4 (loading dose of 4g in 100ml N/S intravenous infusion over 30 minutes, followed by 1g/hr in 100ml N/S continuous IV infusion for 24 hours).
Patients will be treated with standard atropine plus pralidoxime therapy alone.
|
|
Experimental: Atropine plus pralidoxime-Group
Patients will be treated with standard atropine plus pralidoxime therapy alone.
|
Patients will be treated with standard atropine and pralidoxime therapy along with adjunctive MgSO4 (loading dose of 4g in 100ml N/S intravenous infusion over 30 minutes, followed by 1g/hr in 100ml N/S continuous IV infusion for 24 hours).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality
Time Frame: 15 days after hospital admission
|
Frequency of patients will be noted who will die within 15 days to clinical stabilization.
|
15 days after hospital admission
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intermediate Syndrome (IMS)
Time Frame: 7 days after poisoning
|
Frequency of patients will be noted who will develop Intermediate Syndrome (IMS) within seven days of poisoning.
|
7 days after poisoning
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sana Usman, Nishtar Hospital Multan, Pakistan
- Study Director: Arif Mahmood, FCPS, Nishtar Hospital Multan, Pakistan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 10, 2026
Primary Completion (Estimated)
October 10, 2026
Study Completion (Estimated)
October 10, 2026
Study Registration Dates
First Submitted
August 17, 2026
First Submitted That Met QC Criteria
August 17, 2026
First Posted (Actual)
August 20, 2026
Study Record Updates
Last Update Posted (Actual)
August 20, 2026
Last Update Submitted That Met QC Criteria
August 17, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Poisoning
- Organophosphate Poisoning
- Organic Chemicals
- Heterocyclic Compounds
- Alkaloids
- Aza Compounds
- Heterocyclic Compounds, Bridged-Ring
- Atropine Derivatives
- Tropanes
- Azabicyclo Compounds
- Belladonna Alkaloids
- Solanaceous Alkaloids
- Bridged Bicyclo Compounds, Heterocyclic
- Atropine
- pralidoxime
Other Study ID Numbers
- Dr-Sana-Nishter
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Data can be shared on a reasonable request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.